CoChat
Sign Up
Cited by 141

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy

Yao, Han, Wang, Huanbin, Li, Chushu, Fang, Jing-Yuan, Xu, Jie·2018·Frontiers in Immunology
DOI 10.3389/fimmu.2018.01774PMC PMC6077319
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2018.01774

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Distinct signaling pathways involved in programmed death 1 (PD-1)/PD-L1 interaction in the tumor microenvironment. Tumor cells may express both PD-L1 and PD-1, but the downstream signaling of PD-1/PD-L1 interaction that occurs in tumor–tumor or tumor–immune cell interfaces may vary considerably. Both the cell type and tumor type may determine the associated signaling pathways.
Figure 1 Distinct signaling pathways involved in programmed death 1 (PD-1)/PD-L1 interaction in the tumor microenvironment. Tumor cells may express both PD-L1 and PD-1, but the downstream signaling of PD-1/PD-L1 interaction that occurs in tumor–tumor or tumor–immune cell interfaces may vary considerably. Both the cell type and tumor type may determine the associated signaling pathways.CC BY · PubMed Central
Figure 2 Schematic diagram showing that blockade of tumor-intrinsic programmed death 1 (PD-1) suppresses tumor growth in melanoma and liver cancer.
Figure 2 Schematic diagram showing that blockade of tumor-intrinsic programmed death 1 (PD-1) suppresses tumor growth in melanoma and liver cancer.CC BY · PubMed Central
Figure 3 The diagram shows that the blockade of tumor-intrinsic programmed death 1 (PD-1) promotes tumor growth in lung cancer. The interaction between tumor-intrinsic PD-1 and PD-L1 inhibits tumor progression, but the treatment by anti-PD-1 disrupts this inhibitory signaling and promotes tumor progression. This process represents an adverse effect of anti-PD-1 therapy for activating antitumor immunity.
Figure 3 The diagram shows that the blockade of tumor-intrinsic programmed death 1 (PD-1) promotes tumor growth in lung cancer. The interaction between tumor-intrinsic PD-1 and PD-L1 inhibits tumor progression, but the treatment by anti-PD-1 disrupts this inhibitory signaling and promotes tumor progression. This process represents an adverse effect of anti-PD-1 therapy for activating antitumor immunity.CC BY · PubMed Central
Figure 4 Tumor-intrinsic programmed death 1 (PD-1) expression is widespread in many tumor types. (A) PD-1 mRNA expression level analysis in different cancer tissues from the human protein atlas. (B) PD-1 mRNA expression level analysis in various kinds of cancer cells based on related data from Cancer Cell Line Encyclopedia (CCLE). (C). PD-1 protein expression level analysis in different cancer tissues using immunohistochemical staining from the human protein atlas. All cancer types were compared to “Central nervous system” tumors by t-test (P-values indicated). Tumors displaying highly significant differences (P<0.01) are marked by red font.
Figure 4 Tumor-intrinsic programmed death 1 (PD-1) expression is widespread in many tumor types. (A) PD-1 mRNA expression level analysis in different cancer tissues from the human protein atlas. (B) PD-1 mRNA expression level analysis in various kinds of cancer cells based on related data from Cancer Cell Line Encyclopedia (CCLE). (C). PD-1 protein expression level analysis in different cancer tissues using immunohistochemical staining from the human protein atlas. All cancer types were compared to “Central nervous system” tumors by t-test (P-values indicated). Tumors displaying highly significant differences (P<0.01) are marked by red font.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 26

  1. Ishida, 1992, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, EMBO J, 11, 3887, 10.1002/j.1460-2075.1992.tb05481.x · DOI
  2. Fourcade, 2010, Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients, J Exp Med, 207, 2175, 10.1084/jem.20100637 · DOI · Paper page
  3. Wang, 2018, Regulation of PD-L1: emerging routes for targeting tumor immune evasion, Front Pharmacol, 9, 536, 10.3389/fphar.2018.00536 · DOI
  4. Yao, 2014, PD-1 as an immune modulatory receptor, Cancer J, 20, 262, 10.1097/PPO.0000000000000060 · DOI
  5. Page, 2014, Immune modulation in cancer with antibodies, Annu Rev Med, 65, 185, 10.1146/annurev-med-092012-112807 · DOI
  6. Postow, 2015, Immune checkpoint blockade in cancer therapy, J Clin Oncol, 33, 1974, 10.1200/JCO.2014.59.4358 · DOI
  7. Topalian, 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Curr Opin Immunol, 24, 207, 10.1016/j.coi.2011.12.009 · DOI
  8. Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 16, 375, 10.1016/S1470-2045(15)70076-8 · DOI
  9. Dill, 2018, IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1, Mod Pathol, 10.1038/s41379-018-0061-3 · DOI
  10. Masugi, 2017, Tumor PDCD1LG2 (PD-L2) expression and the lymphocytic reaction to colorectal cancer, Cancer Immunol Res, 5, 1046, 10.1158/2326-6066.CIR-17-0122 · DOI
  11. Wang, 2017, PD-L2 expression in colorectal cancer: independent prognostic effect and targetability by deglycosylation, Oncoimmunology, 6, e1327494, 10.1080/2162402X.2017.1327494 · DOI
  12. Schatton, 2008, Identification of cells initiating human melanomas, Nature, 451, 345, 10.1038/nature06489 · DOI
  13. Schatton, 2010, Modulation of T-cell activation by malignant melanoma initiating cells, Cancer Res, 70, 697, 10.1158/0008-5472.CAN-09-1592 · DOI
  14. Callari, 2018, Predicting and understanding cancer response to treatment, Dis Markers, 2018, 6159214, 10.1155/2018/6159214 · DOI
  15. Popivanova, 2008, Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis, J Clin Invest, 118, 560, 10.1172/JCI32453 · DOI
  16. Kleffel, 2015, Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth, Cell, 162, 1242, 10.1016/j.cell.2015.08.052 · DOI
  17. Du, 2018, Blockade of tumor-expressed PD-1 promotes lung cancer growth, Oncoimmunology, 7, e1408747, 10.1080/2162402X.2017.1408747 · DOI
  18. Li, 2017, Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1, Hepatology, 66, 1920, 10.1002/hep.29360 · DOI
  19. Plimack, 2017, Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study, Lancet Oncol, 18, 212, 10.1016/S1470-2045(17)30007-4 · DOI
  20. Teft, 2006, A molecular perspective of CTLA-4 function, Annu Rev Immunol, 24, 65, 10.1146/annurev.immunol.24.021605.090535 · DOI
  21. Mohr, 2018, Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab, J Eur Acad Dermatol Venereol, 32, 962, 10.1111/jdv.14633 · DOI
  22. Philips, 2015, Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies, Int Immunol, 27, 39, 10.1093/intimm/dxu095 · DOI
  23. Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, 369, 134, 10.1056/NEJMoa1305133 · DOI
  24. Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 · DOI · Paper page
  25. Campbell, 2016, Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas, Nat Genet, 48, 607, 10.1038/ng.3564 · DOI · Paper page
  26. Colwill, 2011, A roadmap to generate renewable protein binders to the human proteome, Nat Methods, 8, 551, 10.1038/nmeth.1607 · DOI

Cited by

Sorted by citations

See all 141

Metadata

Authors
Yao, H., Wang, H., Li, C., Fang, J.-Y., & Xu, J.
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2018-07-30
Volume
9
ISSN
1664-3224
DOI
10.3389/fimmu.2018.01774
PMC
PMC6077319
Cited by
141
References
8
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. https://app.cochat.ai/papers/10.3389/fimmu.2018.01774
The paper
Yao, H., Wang, H., Li, C., Fang, J.-Y., & Xu, J. (2018). Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2018.01774